【摘要】 目的评价艾普拉唑、埃索美拉唑、雷贝拉唑3种质子泵抑制剂(PPI)联合氟哌噻吨美利曲辛(黛力新)治疗功能性消化不良的成本-效果,为临床制定合理用药方案。方法抽取2011年功能性消化不良病例119例随机分为A、B、C三组,三组患者均予黛力新片2片,早晨及中午各服1片。A组45例给予艾普拉唑5mg,早餐前1片,B组40例给予埃索美拉唑20mg,早餐前1片,C组34例给予雷贝拉唑10mg,早餐前1片,三组疗程均为28d。各组结果运用药物经济学原理进行成本-效果分析。结果 A、B、C三组治疗功能性消化不良的有效率分别为95.5%、92.5%、91.2%,三组间无显著性差异(P>0.05);成本-效果比(C/E)分别为7.67元、6.06元、6.83元。结论 3种方案治疗功能性消化不良有效率及不良反应发生率无显著性差异,但从药物经济学角度考虑,B组方案较佳。更多还原

【Abstract】 Objective To evaluate the cost-effectiveness of ilaprazole,esomeprazole and rebeprazole in combination with Deanxit for the treatment of functional dyspepsia,in order to a rational medicine regimen in clinical practice.Methods A total of 119 cases with functional dyspepsia in 2011 were randomly divided into 3 groups,A group 45 cses with ilaprazole(5mg),B group 40 cses with esomeprazole(20mg) and C group 34 cses with rebeprazole(10mg) before breakfast,and all patients were assiggned to receive Deanxit(10.5mg) bid after breakfast and lunch.After treatment for 28 days,principle of pharmacoeconomics were adopted to analyze cost-effectiveness of the 3 treatment schemes.Results The effective rates of 3 groups were 95.5%,92.5%,and 91.2% respectively;the cost-effectiveness ratios(C/E) were 7.67,6.06and 6.83 yuan respectively.Conclusion There are no obvious difference of these 3 projects in clinical effective rates of the treatment of functional dyspepsia and the adverse reactions,but in perspective of pharmacoeconomics,scheme B is the best.更多还原